Key result
Age ≥80 years in AMI increased long-term mortality before but not after adjustment for natriuretic peptides.
Why the study?
The ageing population has resulted in more octogenarians experiencing AMI, yet whether chronological age or underlying myocardial dysfunction drives mortality in this population was understudied.
Does chronological age (≥80 years) or underlying heart-failure severity determine all-cause mortality risk in patients with acute myocardial infarction undergoing coronary angiography?
Cohort (n=2,276)
Does chronological age (≥80 years) or underlying heart-failure severity determine all-cause mortality risk in patients with acute myocardial infarction undergoing coronary angiography?
In octogenarians with acute myocardial infarction, higher mortality risk is driven by underlying heart-failure severity (elevated natriuretic peptides and LV systolic or diastolic dysfunction) rather than chronological age itself.
Answers are grounded in this paper and cite their sources.
Age ≥80 signals higher AMI mortality after standard adjustment; leaves open mediation by natriuretic peptides or myocardial dysfunction.
Background: The ageing population has led to more octogenarians experiencing acute myocardial infarction (AMI). Whether age or underlying myocardial dysfunction drives mortality in this population is understudied. We evaluated the impact of age versus cardiac dysfunction on mortality in octogenarians with AMI.Methods: We incorporated AMI patients undergoing coronary angiography from 2004-2019 and stratified them by age ≥ 80 years. All-cause mortality was assessed over median 1.18 years (IQR 0.30–3.86). Multivariable-adjusted Cox regression evaluated age-mortality associations, and Kaplan–Meier analyses assessed survival by natriuretic-peptide levels, left ventricular (LV) ejection fraction (EF), and diastolic function (E/e’).Results: Of 2276 patients (mean age 65.9±13.2years, 73.7%male), 341 (15%) were ≥80. Octogenarians had more multivessel disease, longer ischemia and fluoroscopy times, extended hospitalizations, higher acute kidney injury incidence, and greater impairment in LVEF and myocardial deformation, with more significant mitral regurgitation (all p<0.05). Age ≥80 was associated with higher 30-day, 1-year, and long-term mortality after adjustment for conventional cardiovascular risk factors (HRs 1.97 [1.38–2.82], 1.89 [1.41–2.53], and 1.95 [1.54–2.48]; all p<0.05), but not after ancillary adjustment for natriuretic-peptides. Octogenarians with low natriuretic-peptides or preserved systolic and diastolic function had survival comparable to younger patients, whereas elevated peptides, LVEF<40%, or E/e'≥14 identified higher-risk subgroups (all log-rank p<0.001).Conclusions: In octogenarians with AMI, increased mortality is mediated by reverse causation: the effect of age is driven by heart-failure severity, manifested by elevated natriuretic-peptides and impaired LV systolic or diastolic function. Functional- and biomarker-based, precision-focused prognostic strategy should guide management in octogenarians.
No takes yet. Share an insight, caveat, or question.
Abusharekh et al. (2026) conducted a cohort in Acute myocardial infarction (n=2,276). Age ≥80 years (octogenarians) vs. Age <80 years was evaluated on Long-term all-cause mortality (HR 1.95, 95% CI 1.54-2.48, p=<0.05). Age ≥80 years in AMI increased long-term mortality before but not after adjustment for natriuretic peptides.
Synapse has enriched 10 related papers. Consider them for comparative context: